Company Overview

PRIME exits and American Healthcare Capital are pleased to exclusively represent a premier and highly focused nutritional supplements company specializing in formulating and delivering purified fatty acids with proven health benefits based on studies in cells, humans, and animals. The company manufactures its products in bulk, under contract, and sells them to manufacturers of OTC products that include them as ingredients in a range of nutritional supplement formulations. The company also contract-manufactures a limited range of final products, which it sells directly to retailers under its brand name. Patents that protect the company’s products and methods are in effect in the United States, Australia, Canada, Japan, India, and the EU.

Financial Overview

From 2019 to 2021, topline sales were $1,500,000, with a profit margin of approximately 60% and an average EBITDA of 20%. Direct product sales account for 11% to 16% of total revenue. Total revenue dropped sharply in 2022 due to reduced distributor sales and exiting from the pet supplement sector. The focus during that time was on the development and fundraising efforts for a pivotal clinical trial that would be carried out at a leading medical university. EBITDA is negative (-40%) and includes over $2,000,000 of R&D expenses over the previous four years. There is no obligation to continue the clinical trials in the future.

Staff Overview

The Company operates primarily via contractor relationships. There is a chairman and CEO, and one person leads operations.

Asking Price

The price is to be determined.